Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can matter a great deal when the products solve recurring, expensive problems and the industry is controlled by companies with real distribution muscle.
Chronic Care Is the Real Engine
The report points to atopic dermatitis and osteoarthritis pain as demand drivers, alongside broader pet-health awareness. That tracks. Owners have steadily become more willing to pay for care that keeps an animal comfortable over time, especially when the treatment is targeted and avoids some of the compromises associated with older therapies. Dermatology is expected to post a 5.7% growth rate and retain the largest application share. Skin problems may sound mundane, but they recur, they frustrate owners, and they keep animals coming back through the clinic door.
Monoclonal antibodies are the piece I would watch most closely. They represented 58.2% of the market in 2025 and are expected to be the fastest-growing product category. The attraction is easy enough to grasp: targeted action, potentially durable efficacy, and a path away from broad traditional treatments in certain uses. In livestock, the report also frames these products as tools that may reduce morbidity, improve productivity, and support efforts to curb antimicrobial resistance. Those are meaningful commercial and societal arguments, provided the economics work farm by farm.
Clinics Hold the Customer Relationship
Veterinary hospitals and clinics are projected to grow at 5.8%, the fastest end-user rate in the forecast. That matters because biologics do not sell themselves off a shelf. Diagnosis, prescribing, administration, monitoring, and owner education all run through the veterinary channel. Companies with entrenched clinic relationships, broad sales coverage, diagnostic support, and credible evidence have a practical advantage that a clever early-stage platform cannot simply wish away.
North America is identified as both the largest regional market and the region expected to record the highest growth rate. I would treat the regional commentary with a raised eyebrow, though. The supporting discussion suddenly cites infrastructure and key players in China, India, and Japan, then discusses livestock in India and China. Those are legitimate animal-health markets, but they do not explain a North America claim. Investors should separate the usable demand thesis from the report's muddled geographic framing.
Concentration Is Both Moat and Warning Label
The top five suppliers are estimated to control 79% to 86% of the global market. Zoetis, Merck, Boehringer Ingelheim, Elanco, and Ceva Santé Animale sit in that upper tier. Such concentration usually means formidable regulatory know-how, manufacturing capability, veterinary distribution, and budgets for the long clinical slog. It also means smaller rivals face a rough road even when their science is appealing.
In animal health, a promising molecule is only half the product; the other half is getting veterinarians to trust it and use it repeatedly.
Recent deal activity fits that picture. Boehringer Ingelheim bought Saiba Animal Health in September 2024 for its therapeutic-vaccine platform aimed at chronic companion-animal disease. Zoetis acquired the Veterinary Pathology Group in November 2025, bolstering diagnostics in the United Kingdom and Ireland. The notes also cite a February 2026 merger agreement between Covetrus and MWI Animal Health involving distribution and technology operations. Different assets, same message: buyers want platforms and channel reach, not science-fair projects.
Funding Numbers Need a Pinch of Salt
Broader animal-health investment reportedly fell from $740 million in 2021 to $530 million in 2022, then recovered to $720 million in 2024 and an estimated $780 million in 2025. The report is commendably clear that these are not biologics-only funding figures. Good. Too many market summaries toss an aggregate number on the table and hope nobody notices the category drift.
My takeaway is cautiously constructive. This is a steady, concentrated market with genuine demand drivers in chronic companion-animal care, livestock health, and diagnostics. But a 5.3% forecast is a starting point, not a verdict. Product adoption, reimbursement or owner affordability, clinic behavior, regulatory execution, and actual regional demand will decide who captures the dollars. The winners are likely to be the operators that pair differentiated biologics with trusted veterinary channels, not merely the loudest outfits waving around a growth chart.